Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Cancer treatment reviews - 1 Nov 2010

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S

Abstract excerpt

Metastatic colorectal cancer (mCRC) patients carrying KRAS mutated tumors do not benefit from epidermal growth factor receptor (EGFR)-targeted cetuximab- or panitumumab-based therapies. Indeed, the mutational status of KRAS is currently a validated predictive biomarker employed to select mCRC patients for EGFR targeted drugs. When patients fail standard 5-fluorouracil-, oxaliplatin-, irinotecan- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to Salvage Therapy

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 21129603
DOI: 10.1016/S0305-7372(10)70012-8

Genes

KRAS
EGFR
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.PMID 21129603Read ↗

New strategies for treatment of KRAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.Semantic proximity Read ↗

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Semantic proximity Read ↗

Strategies to tackle RAS-mutated metastatic colorectal cancer.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Semantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.